Viral Inactivation Market by Product (Kits, Reagents, Systems, Services), Application (Stem Cell, Blood, Tissue, Cell & Gene Therapy), Method (Solvent Detergent, Pasteurization) & End User (Pharmaceutical and Biotechnology, CROs) - Global Forecast to 2021
The global viral inactivation market is projected to reach USD 573.0 million by 2021 from USD 320.5 million in 2016, at a CAGR of 12.3% from 2016 to 2020. The major drivers for the market include increase in pharmaceutical and biological industries and increasing number of new drug launches. Over the years, the number of drug approvals in North American countries has increased from 2006 to 2015. In 2015, the FDA’s Center for Drug Evaluation and Research (CDER) approved 45 novel drugs, approved as new molecular entities (NMEs) under New Drug Applications (NDAs) or as new therapeutic biologics under Biologics License Applications (BLAs) as compared to 22 novel drugs approved in 2006. The increasing number of drug approvals will boost the viral inactivation market.
According to OECD estimates, in 2011, the total number of biotechnology companies in the U.S. was 7,970, followed by Spain (3,025 biotechnology companies), and France (1,481 biotechnology companies). Owing to the rise in the number of biotechnology companies, biopharmaceutical production has increased globally. Viral inactivation is carried out at all levels of pharmaceutical and biopharmaceutical manufacturing process to minimize the risk of product contamination. Growth in pharmaceutical and biotechnology industries will drive the growth of the viral inactivation market.
This report segments the global viral inactivation market is segmented based on method, product, application, end user, and geography. The method segments included in the report are solvent detergent method, pasteurization, and other methods. Other viral inactivation method includes low pH, microwave heating, irradiation, and high-energy light.
The product segments included in the report are kits and reagents, services, and viral inactivation systems and accessories.
The application segments included in the report are blood & blood products, cellular & gene therapy products, stem cell products, tissue & tissue products, and vaccines and therapeutics.
Based on end user this market is categorized into pharmaceutical and biotechnology companies, contract research organizations, academic research institutes, and other end users.
The geographic segments included in this report are Asia, Europe, North America and the Rest of the World (RoW). North America is further divided into Canada and the U.S. Asia is further divided in to China, Japan, India, and Rest of Asia.
The report provides qualitative insights on key market shares, growth rates, and market drivers for all important subsegments. It maps market sizes and growth rates of each subsegment and identifies segments poised to see rapid growth. The report also includes company profiles of market leaders. These company profiles include the financial performances, product portfolios, and developments of each company. The report also provides a competitive landscape of the viral inactivation market. The competitive landscape covers the growth strategies adopted by industry players over the last three years. It also includes analyses of industry developments like mergers and acquisitions, agreements and partnerships, and new product launches.
Reasons to Buy the Report:
The report will enable both established firms and new entrants to gauge the pulse of the market and help them make important strategic growth decisions.
The report provides insights on the following:
According to OECD estimates, in 2011, the total number of biotechnology companies in the U.S. was 7,970, followed by Spain (3,025 biotechnology companies), and France (1,481 biotechnology companies). Owing to the rise in the number of biotechnology companies, biopharmaceutical production has increased globally. Viral inactivation is carried out at all levels of pharmaceutical and biopharmaceutical manufacturing process to minimize the risk of product contamination. Growth in pharmaceutical and biotechnology industries will drive the growth of the viral inactivation market.
This report segments the global viral inactivation market is segmented based on method, product, application, end user, and geography. The method segments included in the report are solvent detergent method, pasteurization, and other methods. Other viral inactivation method includes low pH, microwave heating, irradiation, and high-energy light.
The product segments included in the report are kits and reagents, services, and viral inactivation systems and accessories.
The application segments included in the report are blood & blood products, cellular & gene therapy products, stem cell products, tissue & tissue products, and vaccines and therapeutics.
Based on end user this market is categorized into pharmaceutical and biotechnology companies, contract research organizations, academic research institutes, and other end users.
The geographic segments included in this report are Asia, Europe, North America and the Rest of the World (RoW). North America is further divided into Canada and the U.S. Asia is further divided in to China, Japan, India, and Rest of Asia.
The report provides qualitative insights on key market shares, growth rates, and market drivers for all important subsegments. It maps market sizes and growth rates of each subsegment and identifies segments poised to see rapid growth. The report also includes company profiles of market leaders. These company profiles include the financial performances, product portfolios, and developments of each company. The report also provides a competitive landscape of the viral inactivation market. The competitive landscape covers the growth strategies adopted by industry players over the last three years. It also includes analyses of industry developments like mergers and acquisitions, agreements and partnerships, and new product launches.
Reasons to Buy the Report:
The report will enable both established firms and new entrants to gauge the pulse of the market and help them make important strategic growth decisions.
The report provides insights on the following:
- Product Development/Innovation: Product portfolios of top players in the viral inactivation market. Detailed insights on upcoming technologies, research and development activities, and new product launches in the viral inactivation market
- Competitive Assessment: In-depth assessment of market shares, strategies, geographic and business segments, and product portfolios of leading players in the viral inactivation market
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the market for various viral inactivation products across geographies
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 MARKETS COVERED
1.2.2 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 MARKET SIZE ESTIMATION
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION
2.3 MARKET SHARE ESTIMATION
2.3.1 KEY DATA FROM SECONDARY SOURCES
2.3.2 KEY DATA FROM PRIMARY SOURCES
2.3.3 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 GLOBAL VIRAL INACTIVATION MARKET OVERVIEW
4.2 LIFE CYCLE ANALYSIS, BY REGION
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.1.1 MARKET SEGMENTATION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Rapid growth in pharmaceutical and biotechnology industries
5.2.1.2 Increasing number of new drug launches
5.2.1.3 Strong R&D investments in the life sciences industry
5.2.1.4 Increasing government support for pharmaceutical and biotechnology industries
5.2.1.5 High incidence and large economic burden of chronic diseases
5.2.2 RESTRAINT
5.2.2.1 High degree of consolidation to act as a major barrier for new entrants
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing pharmaceutical outsourcing
5.2.3.2 Developing countries present significant growth opportunities for the viral inactivation market
5.2.4 CHALLENGE
5.2.4.1 Stringent regulatory frameworks and time-consuming approval processes for viral inactivation products
6 VIRAL INACTIVATION MARKET, BY METHOD
6.1 INTRODUCTION
6.2 SOLVENT DETERGENT METHOD
6.3 PASTEURIZATION
6.4 OTHER METHODS
7 VIRAL INACTIVATION MARKET, BY PRODUCT
7.1 INTRODUCTION
7.2 KITS AND REAGENTS
7.3 SERVICES
7.4 VIRAL INACTIVATION SYSTEMS AND ACCESSORIES
8 VIRAL INACTIVATION MARKET, BY APPLICATION
8.1 INTRODUCTION
8.2 VACCINES AND THERAPEUTICS
8.3 BLOOD AND BLOOD PRODUCTS
8.4 CELLULAR AND GENE THERAPY PRODUCTS
8.5 TISSUES AND TISSUE PRODUCTS
8.6 STEM CELL PRODUCTS
9 VIRAL INACTIVATION MARKET, BY END USER
9.1 INTRODUCTION
9.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
9.3 CONTRACT RESEARCH ORGANIZATIONS
9.4 ACADEMIC RESEARCH INSTITUTES
9.5 OTHER END USERS
10 VIRAL INACTIVATION MARKET, BY GEOGRAPHY
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 U.S.
10.2.2 CANADA
10.3 EUROPE
10.4 ASIA
10.4.1 CHINA
10.4.2 JAPAN
10.4.3 INDIA
10.4.4 REST OF ASIA
10.5 REST OF THE WORLD
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 STRATEGIC OVERVIEW
11.3 LEADING PLAYERS IN THE VIRAL INACTIVATION MARKET
11.4 COMPETITIVE SITUATION AND TRENDS
11.4.1 EXPANSIONS
11.4.2 ACQUISITIONS
11.4.3 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS
11.4.4 SERVICES LAUNCHES
12 COMPANY PROFILES
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)
12.1 INTRODUCTION
12.2 DANAHER CORPORATION
12.3 MERCK KGAA
12.4 PARKER HANNIFIN CORPORATION
12.5 SARTORIUS AG
12.6 SGS SA
12.7 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
12.8 CLEAN CELLS INC.
12.9 RAD SOURCE TECHNOLOGIES, INC.
12.10 TEXCELL, INC.
12.11 VIRAL INACTIVATED PLASMA SYSTEMS SA
12.12 WUXI PHARMATECH (CAYMAN) INC.
Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
13 APPENDIX
13.1 INSIGHTS OF INDUSTRY EXPERTS
13.2 DISCUSSION GUIDE
13.3 OTHER DEVELOPMENTS
13.4 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.5 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
13.6 AVAILABLE CUSTOMIZATIONS
13.7 RELATED REPORTS
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 MARKETS COVERED
1.2.2 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 MARKET SIZE ESTIMATION
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION
2.3 MARKET SHARE ESTIMATION
2.3.1 KEY DATA FROM SECONDARY SOURCES
2.3.2 KEY DATA FROM PRIMARY SOURCES
2.3.3 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 GLOBAL VIRAL INACTIVATION MARKET OVERVIEW
4.2 LIFE CYCLE ANALYSIS, BY REGION
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.1.1 MARKET SEGMENTATION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Rapid growth in pharmaceutical and biotechnology industries
5.2.1.2 Increasing number of new drug launches
5.2.1.3 Strong R&D investments in the life sciences industry
5.2.1.4 Increasing government support for pharmaceutical and biotechnology industries
5.2.1.5 High incidence and large economic burden of chronic diseases
5.2.2 RESTRAINT
5.2.2.1 High degree of consolidation to act as a major barrier for new entrants
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing pharmaceutical outsourcing
5.2.3.2 Developing countries present significant growth opportunities for the viral inactivation market
5.2.4 CHALLENGE
5.2.4.1 Stringent regulatory frameworks and time-consuming approval processes for viral inactivation products
6 VIRAL INACTIVATION MARKET, BY METHOD
6.1 INTRODUCTION
6.2 SOLVENT DETERGENT METHOD
6.3 PASTEURIZATION
6.4 OTHER METHODS
7 VIRAL INACTIVATION MARKET, BY PRODUCT
7.1 INTRODUCTION
7.2 KITS AND REAGENTS
7.3 SERVICES
7.4 VIRAL INACTIVATION SYSTEMS AND ACCESSORIES
8 VIRAL INACTIVATION MARKET, BY APPLICATION
8.1 INTRODUCTION
8.2 VACCINES AND THERAPEUTICS
8.3 BLOOD AND BLOOD PRODUCTS
8.4 CELLULAR AND GENE THERAPY PRODUCTS
8.5 TISSUES AND TISSUE PRODUCTS
8.6 STEM CELL PRODUCTS
9 VIRAL INACTIVATION MARKET, BY END USER
9.1 INTRODUCTION
9.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
9.3 CONTRACT RESEARCH ORGANIZATIONS
9.4 ACADEMIC RESEARCH INSTITUTES
9.5 OTHER END USERS
10 VIRAL INACTIVATION MARKET, BY GEOGRAPHY
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 U.S.
10.2.2 CANADA
10.3 EUROPE
10.4 ASIA
10.4.1 CHINA
10.4.2 JAPAN
10.4.3 INDIA
10.4.4 REST OF ASIA
10.5 REST OF THE WORLD
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 STRATEGIC OVERVIEW
11.3 LEADING PLAYERS IN THE VIRAL INACTIVATION MARKET
11.4 COMPETITIVE SITUATION AND TRENDS
11.4.1 EXPANSIONS
11.4.2 ACQUISITIONS
11.4.3 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS
11.4.4 SERVICES LAUNCHES
12 COMPANY PROFILES
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)
12.1 INTRODUCTION
12.2 DANAHER CORPORATION
12.3 MERCK KGAA
12.4 PARKER HANNIFIN CORPORATION
12.5 SARTORIUS AG
12.6 SGS SA
12.7 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
12.8 CLEAN CELLS INC.
12.9 RAD SOURCE TECHNOLOGIES, INC.
12.10 TEXCELL, INC.
12.11 VIRAL INACTIVATED PLASMA SYSTEMS SA
12.12 WUXI PHARMATECH (CAYMAN) INC.
Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
13 APPENDIX
13.1 INSIGHTS OF INDUSTRY EXPERTS
13.2 DISCUSSION GUIDE
13.3 OTHER DEVELOPMENTS
13.4 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.5 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
13.6 AVAILABLE CUSTOMIZATIONS
13.7 RELATED REPORTS
LIST OF TABLES
TABLE 1 VIRAL INACTIVATION MARKET SUMMARY
TABLE 2 RAPID GROWTH IN PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES DRIVING THE GROWTH OF THE VIRAL INACTIVATION MARKET
TABLE 3 HIGH DEGREE OF CONSOLIDATION TO RESTRICT ENTRY OF NEW PLAYERS
TABLE 4 INCREASING PHARMACEUTICAL OUTSOURCING TO OFFER SIGNIFICANT GROWTH OPPORTUNITIES IN THE VIRAL INACTIVATION MARKET
TABLE 5 STRINGENT REGULATORY FRAMEWORKS FOR VIRAL INACTIVATION PRODUCTS ARE A MAJOR MARKET CHALLENGE
TABLE 6 VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2014–2021 (USD MILLION)
TABLE 7 VIRAL INACTIVATION MARKET SIZE FOR SOLVENT DETERGENT METHOD, BY REGION, 2014–2021 (USD MILLION)
TABLE 8 VIRAL INACTIVATION MARKET SIZE FOR PASTEURIZATION METHOD, BY REGION, 2014–2021 (USD MILLION)
TABLE 9 VIRAL INACTIVATION MARKET SIZE FOR OTHER METHODS, BY REGION, 2014–2021 (USD MILLION)
TABLE 10 VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
TABLE 11 VIRAL INACTIVATION KITS AND REAGENTS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
TABLE 12 VIRAL INACTIVATION SERVICES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
TABLE 13 VIRAL INACTIVATION SYSTEMS AND ACCESSORIES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
TABLE 14 VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
TABLE 15 VIRAL INACTIVATION MARKET SIZE FOR VACCINES AND THERAPEUTICS, BY REGION, 2014–2021 (USD MILLION)
TABLE 16 VIRAL INACTIVATION MARKET SIZE FOR BLOOD AND BLOOD PRODUCTS, BY REGION, 2014–2021 (USD MILLION)
TABLE 17 VIRAL INACTIVATION MARKET SIZE FOR CELLULAR AND GENE THERAPY PRODUCTS, BY REGION, 2014–2021 (USD MILLION)
TABLE 18 VIRAL INACTIVATION MARKET SIZE FOR TISSUES AND TISSUE PRODUCTS, BY REGION, 2014–2021 (USD MILLION)
TABLE 19 VIRAL INACTIVATION MARKET SIZE FOR STEM CELL PRODUCTS, BY REGION, 2014–2021 (USD MILLION)
TABLE 20 VIRAL INACTIVATION MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
TABLE 21 VIRAL INACTIVATION MARKET SIZE FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2014–2021 (USD MILLION)
TABLE 22 VIRAL INACTIVATION MARKET SIZE FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2014–2021 (USD MILLION)
TABLE 23 VIRAL INACTIVATION MARKET SIZE FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2014–2021 (USD MILLION)
TABLE 24 VIRAL INACTIVATION MARKET SIZE FOR OTHER END USERS, BY REGION, 2014–2021 (USD MILLION)
TABLE 25 VIRAL INACTIVATION MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
TABLE 26 NORTH AMERICA: VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
TABLE 27 NORTH AMERICA: VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
TABLE 28 NORTH AMERICA: VIRAL INACTIVATION MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
TABLE 29 NORTH AMERICA: VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2014–2021 (USD MILLION)
TABLE 30 NORTH AMERICA: VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
TABLE 31 U.S.: VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
TABLE 32 U.S.: VIRAL INACTIVATION MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
TABLE 33 U.S.: VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2014–2021 (USD MILLION)
TABLE 34 U.S.: VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
TABLE 35 CANADA: VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
TABLE 36 CANADA: VIRAL INACTIVATION MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
TABLE 37 CANADA: VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2014–2021 (USD MILLION)
TABLE 38 CANADA: VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
TABLE 39 EUROPE: VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
TABLE 40 EUROPE: VIRAL INACTIVATION MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
TABLE 41 EUROPE: VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2014–2021 (USD MILLION)
TABLE 42 EUROPE: VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
TABLE 43 ASIA: VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
TABLE 44 ASIA: VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
TABLE 45 ASIA: VIRAL INACTIVATION MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
TABLE 46 ASIA: VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2014–2021 (USD MILLION)
TABLE 47 ASIA: VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
TABLE 48 CHINA: VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
TABLE 49 CHINA: VIRAL INACTIVATION MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
TABLE 50 CHINA: VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2014–2021 (USD MILLION)
TABLE 51 CHINA: VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
TABLE 52 JAPAN: VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
TABLE 53 JAPAN: VIRAL INACTIVATION MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
TABLE 54 JAPAN: VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2014–2021 (USD MILLION)
TABLE 55 JAPAN: VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
TABLE 56 INDIA: VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
TABLE 57 INDIA: VIRAL INACTIVATION MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
TABLE 58 INDIA: VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2014–2021 (USD MILLION)
TABLE 59 INDIA: VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
TABLE 60 ROA: VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
TABLE 61 ROA: VIRAL INACTIVATION MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
TABLE 62 ROA: VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2014–2021 (USD MILLION)
TABLE 63 ROA: VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
TABLE 64 ROW: VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
TABLE 65 ROW: VIRAL INACTIVATION MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
TABLE 66 ROW: VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2014–2021 (USD MILLION)
TABLE 67 ROW: VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
TABLE 68 MARKET DEVELOPMENTS BETWEEN 2012 AND 2016
TABLE 69 EXPANSIONS, 2012–2016
TABLE 70 ACQUISITIONS, 2012–2016
TABLE 71 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS, 2012–2016
TABLE 72 SERVICES LAUNCHES, 2012–2015
TABLE 1 VIRAL INACTIVATION MARKET SUMMARY
TABLE 2 RAPID GROWTH IN PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES DRIVING THE GROWTH OF THE VIRAL INACTIVATION MARKET
TABLE 3 HIGH DEGREE OF CONSOLIDATION TO RESTRICT ENTRY OF NEW PLAYERS
TABLE 4 INCREASING PHARMACEUTICAL OUTSOURCING TO OFFER SIGNIFICANT GROWTH OPPORTUNITIES IN THE VIRAL INACTIVATION MARKET
TABLE 5 STRINGENT REGULATORY FRAMEWORKS FOR VIRAL INACTIVATION PRODUCTS ARE A MAJOR MARKET CHALLENGE
TABLE 6 VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2014–2021 (USD MILLION)
TABLE 7 VIRAL INACTIVATION MARKET SIZE FOR SOLVENT DETERGENT METHOD, BY REGION, 2014–2021 (USD MILLION)
TABLE 8 VIRAL INACTIVATION MARKET SIZE FOR PASTEURIZATION METHOD, BY REGION, 2014–2021 (USD MILLION)
TABLE 9 VIRAL INACTIVATION MARKET SIZE FOR OTHER METHODS, BY REGION, 2014–2021 (USD MILLION)
TABLE 10 VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
TABLE 11 VIRAL INACTIVATION KITS AND REAGENTS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
TABLE 12 VIRAL INACTIVATION SERVICES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
TABLE 13 VIRAL INACTIVATION SYSTEMS AND ACCESSORIES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
TABLE 14 VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
TABLE 15 VIRAL INACTIVATION MARKET SIZE FOR VACCINES AND THERAPEUTICS, BY REGION, 2014–2021 (USD MILLION)
TABLE 16 VIRAL INACTIVATION MARKET SIZE FOR BLOOD AND BLOOD PRODUCTS, BY REGION, 2014–2021 (USD MILLION)
TABLE 17 VIRAL INACTIVATION MARKET SIZE FOR CELLULAR AND GENE THERAPY PRODUCTS, BY REGION, 2014–2021 (USD MILLION)
TABLE 18 VIRAL INACTIVATION MARKET SIZE FOR TISSUES AND TISSUE PRODUCTS, BY REGION, 2014–2021 (USD MILLION)
TABLE 19 VIRAL INACTIVATION MARKET SIZE FOR STEM CELL PRODUCTS, BY REGION, 2014–2021 (USD MILLION)
TABLE 20 VIRAL INACTIVATION MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
TABLE 21 VIRAL INACTIVATION MARKET SIZE FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2014–2021 (USD MILLION)
TABLE 22 VIRAL INACTIVATION MARKET SIZE FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2014–2021 (USD MILLION)
TABLE 23 VIRAL INACTIVATION MARKET SIZE FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2014–2021 (USD MILLION)
TABLE 24 VIRAL INACTIVATION MARKET SIZE FOR OTHER END USERS, BY REGION, 2014–2021 (USD MILLION)
TABLE 25 VIRAL INACTIVATION MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
TABLE 26 NORTH AMERICA: VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
TABLE 27 NORTH AMERICA: VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
TABLE 28 NORTH AMERICA: VIRAL INACTIVATION MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
TABLE 29 NORTH AMERICA: VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2014–2021 (USD MILLION)
TABLE 30 NORTH AMERICA: VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
TABLE 31 U.S.: VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
TABLE 32 U.S.: VIRAL INACTIVATION MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
TABLE 33 U.S.: VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2014–2021 (USD MILLION)
TABLE 34 U.S.: VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
TABLE 35 CANADA: VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
TABLE 36 CANADA: VIRAL INACTIVATION MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
TABLE 37 CANADA: VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2014–2021 (USD MILLION)
TABLE 38 CANADA: VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
TABLE 39 EUROPE: VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
TABLE 40 EUROPE: VIRAL INACTIVATION MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
TABLE 41 EUROPE: VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2014–2021 (USD MILLION)
TABLE 42 EUROPE: VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
TABLE 43 ASIA: VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
TABLE 44 ASIA: VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
TABLE 45 ASIA: VIRAL INACTIVATION MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
TABLE 46 ASIA: VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2014–2021 (USD MILLION)
TABLE 47 ASIA: VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
TABLE 48 CHINA: VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
TABLE 49 CHINA: VIRAL INACTIVATION MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
TABLE 50 CHINA: VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2014–2021 (USD MILLION)
TABLE 51 CHINA: VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
TABLE 52 JAPAN: VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
TABLE 53 JAPAN: VIRAL INACTIVATION MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
TABLE 54 JAPAN: VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2014–2021 (USD MILLION)
TABLE 55 JAPAN: VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
TABLE 56 INDIA: VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
TABLE 57 INDIA: VIRAL INACTIVATION MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
TABLE 58 INDIA: VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2014–2021 (USD MILLION)
TABLE 59 INDIA: VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
TABLE 60 ROA: VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
TABLE 61 ROA: VIRAL INACTIVATION MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
TABLE 62 ROA: VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2014–2021 (USD MILLION)
TABLE 63 ROA: VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
TABLE 64 ROW: VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
TABLE 65 ROW: VIRAL INACTIVATION MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
TABLE 66 ROW: VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2014–2021 (USD MILLION)
TABLE 67 ROW: VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
TABLE 68 MARKET DEVELOPMENTS BETWEEN 2012 AND 2016
TABLE 69 EXPANSIONS, 2012–2016
TABLE 70 ACQUISITIONS, 2012–2016
TABLE 71 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS, 2012–2016
TABLE 72 SERVICES LAUNCHES, 2012–2015
LIST OF FIGURES
FIGURE 1 GLOBAL VIRAL INACTIVATION MARKET
FIGURE 2 RESEARCH DESIGN
FIGURE 3 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
FIGURE 4 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 6 DATA TRIANGULATION METHODOLOGY
FIGURE 7 VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2016 VS. 2021 (USD MILLION)
FIGURE 8 VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2016 VS. 2021 (USD MILLION)
FIGURE 9 VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2016 VS. 2021 (USD MILLION)
FIGURE 10 VIRAL INACTIVATION MARKET SIZE, BY END USER, 2016 VS. 2021 (USD MILLION)
FIGURE 11 VIRAL INACTIVATION MARKET SIZE, BY REGION, 2016 VS. 2021 USD MILLION)
FIGURE 12 GROWTH IN PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES WILL DRIVE THE VIRAL INACTIVATION MARKET DURING THE FORECAST PERIOD (2016-2021)
FIGURE 13 KITS AND REAGENTS PRODUCT SEGMENT TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2016
FIGURE 14 ASIA TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD
FIGURE 15 ASIA HOLDS LUCRATIVE GROWTH OPPORTUNITIES
FIGURE 16 VIRAL INACTIVATION MARKET SEGMENTATION
FIGURE 17 VIRAL INACTIVATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
FIGURE 18 NUMBER OF NEW PHARMACEUTICAL DRUG LAUNCHED, 2003–2013
FIGURE 19 VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2016 (USD MILLION)
FIGURE 20 NORTH AMERICA TO DOMINATE THE SOLVENT DETERGENT METHOD SEGMENT IN 2016
FIGURE 21 NORTH AMERICA TO DOMINATE THE PASTEURIZATION SEGMENT IN 2016
FIGURE 22 NORTH AMERICA TO DOMINATE THE OTHER METHODS SEGMENT IN 2016
FIGURE 23 KITS AND REAGENTS TO FORM THE LARGEST PRODUCT SEGMENT IN 2016
FIGURE 24 NORTH AMERICA TO DOMINATE THE VIRAL INACTIVATION KITS AND REAGENTS MARKET IN 2016
FIGURE 25 NORTH AMERICA TO COMMAND THE LARGEST SHARE OF THE VIRAL INACTIVATION SERVICES MARKET IN 2016
FIGURE 26 NORTH AMERICA TO COMMAND THE LARGEST SHARE OF THE VIRAL INACTIVATION SYSTEMS AND ACCESSORIES MARKET IN 2016
FIGURE 27 VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2016 (USD MILLION)
FIGURE 28 NORTH AMERICA TO DOMINATE THE VACCINES AND THERAPEUTICS SEGMENT IN 2016
FIGURE 29 NORTH AMERICA HOLDS THE LARGEST SHARE IN THE BLOOD AND BLOOD PRODUCTS SEGMENT IN 2016
FIGURE 30 ASIA TO WITNESS HIGHEST GROWTH IN THE CELLULAR AND GENE THERAPY PRODUCTS SEGMENT DURING THE FORECAST PERIOD
FIGURE 31 NORTH AMERICA TO COMMAND LARGEST SHARE OF THE TISSUES AND TISSUE PRODUCTS SEGMENT DURING THE FORECAST PERIOD
FIGURE 32 ASIA TO WITNESS HIGHEST GROWTH IN THE STEM CELL PRODUCTS SEGMENT DURING THE FORECAST PERIOD
FIGURE 33 VIRAL INACTIVATION MARKET, BY END USER
FIGURE 34 VIRAL INACTIVATION MARKET SIZE, BY END USER, 2016 (USD MILLION)
FIGURE 35 NORTH AMERICA TO DOMINATE THE PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES END-USER SEGMENT DURING THE FORECAST PERIOD
FIGURE 36 ASIA TO WITNESS THE HIGHEST GROWTH IN THE CONTRACT RESEARCH ORGANIZATION END-USER SEGMENT DURING THE FORECAST PERIOD
FIGURE 37 ASIA TO WITNESS THE HIGHEST GROWTH IN THE ACADEMIC RESEARCH INSTITUTES END-USER SEGMENT DURING THE FORECAST PERIOD
FIGURE 38 NORTH AMERICA TO DOMINATE THE OTHER END USERS SEGMENT DURING THE FORECAST PERIOD
FIGURE 39 NORTH AMERICA TO DOMINATE THE GLOBAL VIRAL INACTIVATION MARKET IN 2016
FIGURE 40 ASIAN VIRAL INACTIVATION MARKET TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD (2016–2021)
FIGURE 41 NORTH AMERICA: VIRAL INACTIVATION MARKET SNAPSHOT
FIGURE 42 U.S. TO WITNESS HIGHEST GROWTH IN THE NORTH AMERICAN VIRAL INACTIVATION MARKET DURING THE FORECAST PERIOD (2016–2021)
FIGURE 43 VACCINES AND THERAPEUTICS SEGMENT TO COMMAND THE LARGEST SHARE OF THE NORTH AMERICAN VIRAL INACTIVATION MARKET IN 2016
FIGURE 44 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO DOMINATE THE NORTH AMERICAN VIRAL INACTIVATION END-USER MARKET IN 2016
FIGURE 45 SOLVENT DETERGENT METHOD SEGMENT TO DOMINATE THE NORTH AMERICAN MARKET IN 2016
FIGURE 46 KITS AND REAGENTS ESTIMATED TO FORM THE LARGEST PRODUCT SEGMENT IN THE NORTH AMERICAN VIRAL INACTIVATION MARKET IN 2016
FIGURE 47 VACCINES AND THERAPEUTICS SEGMENT TO COMMAND THE LARGEST SHARE OF THE EUROPEAN VIRAL INACTIVATION MARKET IN 2016
FIGURE 48 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO DOMINATE THE EUROPEAN VIRAL INACTIVATION END-USERS MARKET IN 2016
FIGURE 49 SOLVENT DETERGENT METHODS SEGMENT TO DOMINATE THE VIRAL INACTIVATION MARKET IN EUROPE IN 2016
FIGURE 50 KITS AND REAGENTS TO FORM THE LARGEST PRODUCT SEGMENT IN THE EUROPEAN VIRAL INACTIVATION MARKET IN 2016
FIGURE 51 ASIA: VIRAL INACTIVATION MARKET SNAPSHOT
FIGURE 52 CHINA TO WITNESS HIGHEST GROWTH IN THE ASIAN VIRAL INACTIVATION MARKET IN 2016
FIGURE 53 VACCINES AND THERAPEUTICS SEGMENT TO COMMAND THE LARGEST SHARE OF THE ASIAN VIRAL INACTIVATION MARKET IN 2016
FIGURE 54 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO DOMINATE THE ASIAN VIRAL INACTIVATION END-USERS MARKET IN 2016
FIGURE 55 SOLVENT DETERGENT METHOD SEGMENT TO DOMINATE THE ASIAN MARKET IN 2016
FIGURE 56 KITS AND REAGENTS ESTIMATED TO FORM THE LARGEST PRODUCT SEGMENT IN THE ASIAN VIRAL INACTIVATION MARKET IN 2016
FIGURE 57 VACCINES AND THERAPEUTICS SEGMENT TO COMMAND THE LARGEST SHARE OF THE VIRAL INACTIVATION MARKET IN THE REST OF THE WORLD IN 2016
FIGURE 58 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO DOMINATE THE VIRAL INACTIVATION END-USERS MARKET IN THE REST OF THE WORLD IN 2016
FIGURE 59 SOLVENT DETERGENT METHOD SEGMENT TO DOMINATE THE VIRAL INACTIVATION MARKET IN THE REST OF THE WORLD REGION IN 2016
FIGURE 60 KITS AND REAGENTS TO FORM THE LARGEST VIRAL INACTIVATION PRODUCT SEGMENT IN THE REST OF THE WORLD REGION IN 2016
FIGURE 61 EXPANSIONS AND ACQUISITIONS—KEY STRATEGIES ADOPTED BY PLAYERS
FIGURE 62 VIRAL INACTIVATION MARKET SHARE ANALYSIS, BY KEY PLAYER, 2015
FIGURE 63 FINANCIAL PERFORMANCE OF LEADING MARKET PLAYERS (2013–2015)
FIGURE 64 COMPANY SNAPSHOT: DANAHER CORPORATION
FIGURE 65 COMPANY SNAPSHOT: MERCK KGAA
FIGURE 66 COMPANY SNAPSHOT: PARKER HANNIFIN CORPORATION
FIGURE 67 COMPANY SNAPSHOT: SARTORIUS AG
FIGURE 68 COMPANY SNAPSHOT: SGS SA
FIGURE 69 COMPANY SNAPSHOT: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
FIGURE 70 COMPANY SNAPSHOT: WUXI PHARMATECH (CAYMAN) INC.
FIGURE 1 GLOBAL VIRAL INACTIVATION MARKET
FIGURE 2 RESEARCH DESIGN
FIGURE 3 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
FIGURE 4 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 6 DATA TRIANGULATION METHODOLOGY
FIGURE 7 VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2016 VS. 2021 (USD MILLION)
FIGURE 8 VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2016 VS. 2021 (USD MILLION)
FIGURE 9 VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2016 VS. 2021 (USD MILLION)
FIGURE 10 VIRAL INACTIVATION MARKET SIZE, BY END USER, 2016 VS. 2021 (USD MILLION)
FIGURE 11 VIRAL INACTIVATION MARKET SIZE, BY REGION, 2016 VS. 2021 USD MILLION)
FIGURE 12 GROWTH IN PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES WILL DRIVE THE VIRAL INACTIVATION MARKET DURING THE FORECAST PERIOD (2016-2021)
FIGURE 13 KITS AND REAGENTS PRODUCT SEGMENT TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2016
FIGURE 14 ASIA TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD
FIGURE 15 ASIA HOLDS LUCRATIVE GROWTH OPPORTUNITIES
FIGURE 16 VIRAL INACTIVATION MARKET SEGMENTATION
FIGURE 17 VIRAL INACTIVATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
FIGURE 18 NUMBER OF NEW PHARMACEUTICAL DRUG LAUNCHED, 2003–2013
FIGURE 19 VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2016 (USD MILLION)
FIGURE 20 NORTH AMERICA TO DOMINATE THE SOLVENT DETERGENT METHOD SEGMENT IN 2016
FIGURE 21 NORTH AMERICA TO DOMINATE THE PASTEURIZATION SEGMENT IN 2016
FIGURE 22 NORTH AMERICA TO DOMINATE THE OTHER METHODS SEGMENT IN 2016
FIGURE 23 KITS AND REAGENTS TO FORM THE LARGEST PRODUCT SEGMENT IN 2016
FIGURE 24 NORTH AMERICA TO DOMINATE THE VIRAL INACTIVATION KITS AND REAGENTS MARKET IN 2016
FIGURE 25 NORTH AMERICA TO COMMAND THE LARGEST SHARE OF THE VIRAL INACTIVATION SERVICES MARKET IN 2016
FIGURE 26 NORTH AMERICA TO COMMAND THE LARGEST SHARE OF THE VIRAL INACTIVATION SYSTEMS AND ACCESSORIES MARKET IN 2016
FIGURE 27 VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2016 (USD MILLION)
FIGURE 28 NORTH AMERICA TO DOMINATE THE VACCINES AND THERAPEUTICS SEGMENT IN 2016
FIGURE 29 NORTH AMERICA HOLDS THE LARGEST SHARE IN THE BLOOD AND BLOOD PRODUCTS SEGMENT IN 2016
FIGURE 30 ASIA TO WITNESS HIGHEST GROWTH IN THE CELLULAR AND GENE THERAPY PRODUCTS SEGMENT DURING THE FORECAST PERIOD
FIGURE 31 NORTH AMERICA TO COMMAND LARGEST SHARE OF THE TISSUES AND TISSUE PRODUCTS SEGMENT DURING THE FORECAST PERIOD
FIGURE 32 ASIA TO WITNESS HIGHEST GROWTH IN THE STEM CELL PRODUCTS SEGMENT DURING THE FORECAST PERIOD
FIGURE 33 VIRAL INACTIVATION MARKET, BY END USER
FIGURE 34 VIRAL INACTIVATION MARKET SIZE, BY END USER, 2016 (USD MILLION)
FIGURE 35 NORTH AMERICA TO DOMINATE THE PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES END-USER SEGMENT DURING THE FORECAST PERIOD
FIGURE 36 ASIA TO WITNESS THE HIGHEST GROWTH IN THE CONTRACT RESEARCH ORGANIZATION END-USER SEGMENT DURING THE FORECAST PERIOD
FIGURE 37 ASIA TO WITNESS THE HIGHEST GROWTH IN THE ACADEMIC RESEARCH INSTITUTES END-USER SEGMENT DURING THE FORECAST PERIOD
FIGURE 38 NORTH AMERICA TO DOMINATE THE OTHER END USERS SEGMENT DURING THE FORECAST PERIOD
FIGURE 39 NORTH AMERICA TO DOMINATE THE GLOBAL VIRAL INACTIVATION MARKET IN 2016
FIGURE 40 ASIAN VIRAL INACTIVATION MARKET TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD (2016–2021)
FIGURE 41 NORTH AMERICA: VIRAL INACTIVATION MARKET SNAPSHOT
FIGURE 42 U.S. TO WITNESS HIGHEST GROWTH IN THE NORTH AMERICAN VIRAL INACTIVATION MARKET DURING THE FORECAST PERIOD (2016–2021)
FIGURE 43 VACCINES AND THERAPEUTICS SEGMENT TO COMMAND THE LARGEST SHARE OF THE NORTH AMERICAN VIRAL INACTIVATION MARKET IN 2016
FIGURE 44 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO DOMINATE THE NORTH AMERICAN VIRAL INACTIVATION END-USER MARKET IN 2016
FIGURE 45 SOLVENT DETERGENT METHOD SEGMENT TO DOMINATE THE NORTH AMERICAN MARKET IN 2016
FIGURE 46 KITS AND REAGENTS ESTIMATED TO FORM THE LARGEST PRODUCT SEGMENT IN THE NORTH AMERICAN VIRAL INACTIVATION MARKET IN 2016
FIGURE 47 VACCINES AND THERAPEUTICS SEGMENT TO COMMAND THE LARGEST SHARE OF THE EUROPEAN VIRAL INACTIVATION MARKET IN 2016
FIGURE 48 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO DOMINATE THE EUROPEAN VIRAL INACTIVATION END-USERS MARKET IN 2016
FIGURE 49 SOLVENT DETERGENT METHODS SEGMENT TO DOMINATE THE VIRAL INACTIVATION MARKET IN EUROPE IN 2016
FIGURE 50 KITS AND REAGENTS TO FORM THE LARGEST PRODUCT SEGMENT IN THE EUROPEAN VIRAL INACTIVATION MARKET IN 2016
FIGURE 51 ASIA: VIRAL INACTIVATION MARKET SNAPSHOT
FIGURE 52 CHINA TO WITNESS HIGHEST GROWTH IN THE ASIAN VIRAL INACTIVATION MARKET IN 2016
FIGURE 53 VACCINES AND THERAPEUTICS SEGMENT TO COMMAND THE LARGEST SHARE OF THE ASIAN VIRAL INACTIVATION MARKET IN 2016
FIGURE 54 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO DOMINATE THE ASIAN VIRAL INACTIVATION END-USERS MARKET IN 2016
FIGURE 55 SOLVENT DETERGENT METHOD SEGMENT TO DOMINATE THE ASIAN MARKET IN 2016
FIGURE 56 KITS AND REAGENTS ESTIMATED TO FORM THE LARGEST PRODUCT SEGMENT IN THE ASIAN VIRAL INACTIVATION MARKET IN 2016
FIGURE 57 VACCINES AND THERAPEUTICS SEGMENT TO COMMAND THE LARGEST SHARE OF THE VIRAL INACTIVATION MARKET IN THE REST OF THE WORLD IN 2016
FIGURE 58 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO DOMINATE THE VIRAL INACTIVATION END-USERS MARKET IN THE REST OF THE WORLD IN 2016
FIGURE 59 SOLVENT DETERGENT METHOD SEGMENT TO DOMINATE THE VIRAL INACTIVATION MARKET IN THE REST OF THE WORLD REGION IN 2016
FIGURE 60 KITS AND REAGENTS TO FORM THE LARGEST VIRAL INACTIVATION PRODUCT SEGMENT IN THE REST OF THE WORLD REGION IN 2016
FIGURE 61 EXPANSIONS AND ACQUISITIONS—KEY STRATEGIES ADOPTED BY PLAYERS
FIGURE 62 VIRAL INACTIVATION MARKET SHARE ANALYSIS, BY KEY PLAYER, 2015
FIGURE 63 FINANCIAL PERFORMANCE OF LEADING MARKET PLAYERS (2013–2015)
FIGURE 64 COMPANY SNAPSHOT: DANAHER CORPORATION
FIGURE 65 COMPANY SNAPSHOT: MERCK KGAA
FIGURE 66 COMPANY SNAPSHOT: PARKER HANNIFIN CORPORATION
FIGURE 67 COMPANY SNAPSHOT: SARTORIUS AG
FIGURE 68 COMPANY SNAPSHOT: SGS SA
FIGURE 69 COMPANY SNAPSHOT: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
FIGURE 70 COMPANY SNAPSHOT: WUXI PHARMATECH (CAYMAN) INC.
